These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15853723)

  • 1. C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences.
    Bower JF; Sanders KL; Ross TM
    Curr HIV Res; 2005 Apr; 3(2):191-8. PubMed ID: 15853723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
    Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.
    Bower JF; Yang X; Sodroski J; Ross TM
    J Virol; 2004 May; 78(9):4710-9. PubMed ID: 15078953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.
    Green TD; Montefiori DC; Ross TM
    J Virol; 2003 Feb; 77(3):2046-55. PubMed ID: 12525639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model.
    Liu F; Mboudjeka I; Shen S; Chou TH; Wang S; Ross TM; Lu S
    Vaccine; 2004 Apr; 22(13-14):1764-72. PubMed ID: 15068860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse strain-dependent differences in enhancement of immune responses by C3d.
    Toapanta FR; Ross TM
    Vaccine; 2004 Apr; 22(13-14):1773-81. PubMed ID: 15068861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.
    Ross TM; Xu Y; Green TD; Montefiori DC; Robinson HL
    AIDS Res Hum Retroviruses; 2001 Jun; 17(9):829-35. PubMed ID: 11429124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A minimum CR2 binding domain of C3d enhances immunity following vaccination.
    Bower JF; Ross TM
    Adv Exp Med Biol; 2006; 586():249-64. PubMed ID: 16893077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses.
    Megati S; Garcia-Hand D; Cappello S; Roopchand V; Masood A; Xu R; Luckay A; Chong SY; Rosati M; Sackitey S; Weiner DB; Felber BK; Pavlakis GN; Israel ZR; Smith LR; Eldridge JH; Sidhu MK; Egan MA
    Vaccine; 2008 Sep; 26(40):5083-94. PubMed ID: 18485543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons.
    Corbet S; Vinner L; Hougaard DM; Bryder K; Nielsen HV; Nielsen C; Fomsgaard A
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1997-2008. PubMed ID: 11153083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons.
    Vinner L; Nielsen HV; Bryder K; Corbet S; Nielsen C; Fomsgaard A
    Vaccine; 1999 Apr; 17(17):2166-75. PubMed ID: 10367950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime.
    Smith JM; Amara RR; Campbell D; Xu Y; Patel M; Sharma S; Butera ST; Ellenberger DL; Yi H; Chennareddi L; Herndon JG; Wyatt LS; Montefiori D; Moss B; McClure HM; Robinson HL
    AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1335-47. PubMed ID: 15650426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.
    Pantaleo G; Janes H; Karuna S; Grant S; Ouedraogo GL; Allen M; Tomaras GD; Frahm N; Montefiori DC; Ferrari G; Ding S; Lee C; Robb ML; Esteban M; Wagner R; Bart PA; Rettby N; McElrath MJ; Gilbert PB; Kublin JG; Corey L;
    Lancet HIV; 2019 Nov; 6(11):e737-e749. PubMed ID: 31601541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
    Bower JF; Li Y; Wyatt R; Ross TM
    Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity.
    Shata MT; Hone DM
    J Virol; 2001 Oct; 75(20):9665-70. PubMed ID: 11559798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of immune responses to an HIV env DNA vaccine by a C-terminal segment of listeriolysin O.
    Bu Z; Ye L; Skeen MJ; Ziegler HK; Compans RW; Yang C
    AIDS Res Hum Retroviruses; 2003 May; 19(5):409-20. PubMed ID: 12803999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques.
    Li J; Valentin A; Kulkarni V; Rosati M; Beach RK; Alicea C; Hannaman D; Reed SG; Felber BK; Pavlakis GN
    Vaccine; 2013 Aug; 31(36):3747-55. PubMed ID: 23624057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.